Published in Medical Letter on the CDC and FDA, February 6th, 2005
SuperGen's decision to withdraw the filing was based on discussions with both the FDA and consultants helping the company dialog with the agency regarding the Orathecin NDA.
SuperGen originally submitted the NDA for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.